Pyruvate dehydrogenase lipoamide kinase isozyme 4, mitochondrial (PDK4)

Pyruvate dehydrogenase kinase 4 (PDK4) is a mitochondrial serine/threonine kinase belonging to the PDK/BCKDK family[1][4]. It phosphorylates and inactivates the pyruvate dehydrogenase complex (PDC), thereby regulating the conversion of pyruvate to acetyl-CoA, a pivotal step in controlling the balance between carbohydrate and fat metabolism[1][2][3]. Expression of PDK4 is tissue-specific, with high levels in skeletal muscle, heart, liver, kidney, and pancreatic islets[3][4]. It is induced under conditions such as fasting, diabetes, and increased glucocorticoid or retinoic acid activity, helping the body conserve glucose by slowing its conversion to energy[1][3]. PDK4 has gained clinical interest as a potential therapeutic target in cancer, diabetes, and cardiovascular disease, particularly because inhibition of PDK4 enhances pyruvate oxidation and can suppress disease progression in several cancer models[2][7][8]. Pharmacological inhibitors such as dichloroacetate and specific PDK4 antagonists are under investigation for their ability to modulate metabolic pathways and treat related diseases[2][7]. Safety challenges remain, especially regarding metabolic side effects or non-selective inhibition[2][7].

Other names

Pyruvate dehydrogenase kinase 4PDK4Pyruvate dehydrogenase complex kinase 4Pyruvate dehydrogenase lipoamide kinase isozyme 4, mitochondrial

Inhibitors of PDK4 block phosphorylation of the pyruvate dehydrogenase complex, reactivating PDH and promoting pyruvate oxidation to acetyl-CoA. This shifts metabolism from glycolysis/lactate production towards mitochondrial oxidation, affecting cell proliferation and energy production.